Medicare Drug Prices: CMS Releases 2027 Negotiated Prices Under Inflation Reduction Act

Medicare Drug Negotiation Details

• 🎯 The Centers for Medicare and Medicaid Services (CMS) have released the negotiated prices for several drugs under the Inflation Reduction Act.
• 🗓️ These new prices will take effect starting in 2027 for Medicare Part D.

Key Drug Price Reductions

• 💡 For diabetes drugs, Goi and Rebelsis will have a negotiated price of $274, which is 71% below the list price. However, the MFN price of $245 will prevail.
• 💊 Janu for type 2 diabetes by Merck will be priced at $80, representing an 85% discount from the list price.
• 📉 Tragenta from Boehringer Ingelheim will be $78, also an 84% reduction from its list price.

Cancer Drug Pricing

• 🔬 The most significant price reductions are seen in cancer drugs, particularly polyomist for myoma.
• 💰 This blood cancer drug will have a negotiated price of $86.50, a 60% discount from its list price.